News | September 12, 2024
AGC and Medinet sign agreement for cell therapy CDMO business
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
